SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Johns Hopkins University said it would eliminate more than 2,000 jobs after the Trump administration rescinded funding for ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...